Brain, Vol. 124, No. 1, 145-153,
January 2001
© 2001 Oxford University Press
Intravenous immunoglobulin therapy in multifocal motor neuropathy
A double-blind, placebo-controlled study
1 Fédération de Neurologie Mazarin, 2 Service d'Explorations Fonctionnelles-Neurologie, 3 Laboratoire d'Immunochimie, 4 4INSERM U495, Groupe Neuropathies Périphériques Pitié-Salpêtrière (GNPS), Hôpital de la Salpêtrière, Paris, France
Correspondence to:
Dr J.-M. Léger, Fédération de Neurologie Mazarin, Hôpital de la Salpêtrière, 47 boulevard de l'Hôpital, 75651 Paris cedex 13, France E-mail: jean-marc.leger{at}psl.ap-hop-paris.fr
We conducted a double-blind, placebo-controlled, study of 19 patients fulfilling eligibility criteria for multifocal motor neuropathy with persistent conduction block. They were enrolled and divided into two groups: those who had never been treated previously with intravenous immunoglobulins (IVIg) (Group 1: 10 patients) and those who presented recurrent symptoms after previously successful treatment with IVIg (Group 2: nine patients). They were randomized prospectively to receive either IVIg or placebo at a dose of 500 mg/kg/day for 5 consecutive days, once a month for 3 months. At month 4, patients found to be responders remained on the same treatment for the 3 following months, while non-responders were switched to the alternative study drug for the 3 following months. Clinical assessment was conducted with the MRC score in 28 muscles and a self-evaluation scale (five daily motor activities scored from 0 to 5). In Group 1, nine patients completed the study, of whom initially four received IVIg and five placebo; four patients responded to IVIg (two at months 4 and 7, and a further two at month 7 after switching treatment at month 4), two patients responded to placebo at months 4 and 7, and three patients did not respond to either treatment. In Group 2, nine patients completed the study. Five patients first received IVIg and all responded at months 4 and 7. Four patients first received placebo and none responded at month 4; all were then switched to IVIg and three responded at month 7. When the 18 patients were considered together, seven out of the nine patients who received IVIg first were responders at month 4, compared with two of the nine patients who received placebo first, a difference that was statistically significant (P = 0.03). On the other hand, there was no significant difference in MRC score but a significant difference in the self-evaluation score, at month 4, between IVIg patients and placebo patients. Electrophysiological studies did not show significant differences at month 4 in motor parameters between IVIg patients and placebo patients. IgM anti-GM1 titres did not change significantly in patients treated with IVIg compared with those who received placebo, between baseline, month 4 and month 7. However, of five patients who had significantly high anti-GM1 titres (>3200) at baseline, four responded to IVIg. This trial confirms that IVIg is a promising therapeutic option for multifocal motor neuropathy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. C. Lehmann, G. Meyer zu Horste, B. C. Kieseier, and H.-P. Hartung Review: Pathogenesis and treatment of immune-mediated neuropathies Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 261 - 281. [Abstract] [PDF]
|
|
|
|
|
|
M. Stangel Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 115 - 124. [Abstract] [PDF]
|
|
|
|
 |
|
 Y A Rajabally Multifocal motor neuropathy: review of a treatable immune mediated disorder Postgrad. Med. J., June 1, 2008; 84(992): 287 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J-M Leger, K Viala, F Cancalon, T Maisonobe, B Gruwez, T Waegemans, and P Bouche Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients J. Neurol. Neurosurg. Psychiatry, January 1, 2008; 79(1): 93 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Slee, A. Selvan, and M. Donaghy Multifocal motor neuropathy: The diagnostic spectrum and response to treatment Neurology, October 23, 2007; 69(17): 1680 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Piepers, R. Van den Berg-Vos, W-L. Van der Pol, H. Franssen, J. Wokke, and L. Van den Berg Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial Brain, August 1, 2007; 130(8): 2004 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S Baek and N. P Desai ALS: pitfalls in the diagnosis Practical Neurology, April 1, 2007; 7(2): 74 - 81. [Full Text] [PDF]
|
|
|
|
|
|
E. Delmont, J. P. Azulay, R. Giorgi, S. Attarian, A. Verschueren, D. Uzenot, and J. Pouget Multifocal motor neuropathy with and without conduction block: a single entity? Neurology, August 22, 2006; 67(4): 592 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nodera, H. Bostock, Y. Izumi, K. Nakamura, R. Urushihara, T. Sakamoto, N. Murase, H. Shimazu, S. Kusunoki, and R. Kaji Activity-dependent conduction block in multifocal motor neuropathy: magnetic fatigue test. Neurology, July 25, 2006; 67(2): 280 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J T H Van Asseldonk, L H Van den Berg, S Kalmijn, R M Van den Berg-Vos, C H Polman, J H J Wokke, and H Franssen Axon loss is an important determinant of weakness in multifocal motor neuropathy. J. Neurol. Neurosurg. Psychiatry, June 1, 2006; 77(6): 743 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Ruegg, P. Fuhr, and A. J. Steck Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg Neurology, December 14, 2004; 63(11): 2178 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vucic, K. R. Black, P. S. T. Chong, and D. Cros Multifocal motor neuropathy: Decrease in conduction blocks and reinnervation with long-term IVIg Neurology, October 12, 2004; 63(7): 1264 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Viala, L. Renie, T. Maisonobe, A. Behin, J. Neil, J. M. Leger, and P. Bouche Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome Brain, September 1, 2004; 127(9): 2010 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Terenghi, A. Cappellari, A. Bersano, M. Carpo, S. Barbieri, and E. Nobile-Orazio How long is IVIg effective in multifocal motor neuropathy? Neurology, February 24, 2004; 62(4): 666 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Pestronk, J Florence, T Miller, R Choksi, M T Al-Lozi, and T D Levine Treatment of IgM antibody associated polyneuropathies using rituximab J. Neurol. Neurosurg. Psychiatry, April 1, 2003; 74(4): 485 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. H. Van Asseldonk, L. H. Van den Berg, R. M. Van den Berg-Vos, G. H. Wieneke, J. H. J. Wokke, and H. Franssen Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness Brain, January 1, 2003; 126(1): 186 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Koski Therapy of CIDP and related immune-mediated neuropathies Neurology, December 24, 2002; 59(90126): S22 - 27. [Abstract] [Full Text]
|
|
|
|
|
|
H. J. Willison and N. Yuki Peripheral neuropathies and anti-glycolipid antibodies Brain, December 1, 2002; 125(12): 2591 - 2625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Van den Berg-Vos, H. Franssen, J. H. J. Wokke, and L. H. V. d. Berg Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment Brain, August 1, 2002; 125(8): 1875 - 1886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Nobile-Orazio, A Cappellari, N Meucci, M Carpo, F Terenghi, A Bersano, A Priori, S Barbieri, and G Scarlato Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block J. Neurol. Neurosurg. Psychiatry, June 1, 2002; 72(6): 761 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al. Intravenous immunoglobulin in neurological disease: a specialist review J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Willison, C. P. O'Leary, J. Veitch, L. D. Blumhardt, M. Busby, M. Donaghy, P. Fuhr, H. Ford, A. Hahn, S. Renaud, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies Brain, October 1, 2001; 124(10): 1968 - 1977. [Abstract] [Full Text] [PDF]
|
|